Merck and Millipore have entered into a definitive agreement under which Merck will acquire all outstanding shares of common stock of Millipore for US$107 per share in cash, or a total transaction value, including net debt, of approximately US$7.2 billion.
The transaction was approved by the boards of directors of both companies. Millipore and Merck will create a US$ 2.9 billion partnership for the Life Science sector.
Millipore offers a comprehensive range of products, technologies and services for pharma and biotech companies, as well as for academia, to improve laboratory productivity and to develop and optimise manufacturing processes.
Currently the Chemicals business sector generates around 25% of Merck’s total revenues. Following the transaction, the chemicals business will contribute 35% of total Group revenues of driven by its Liquid Crystals business and the new life science business.
The company plans to maintain Millipore’s headquarters in Billerica, Massachusetts, US and combine it with Merck’s US chemicals headquarters.
Add a comment